Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
02 nov. 2022 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2022 total revenue of $90.7 million and Crysvita® revenue in Ultragenyx territories1 of $64.5 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million...
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
27 oct. 2022 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2022 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx anuncia el reconocimiento de medicamento huérfano de Dojolvi® (triheptanoína) en México para el tratamiento de los trastornos de oxidación de ácidos grasos de cadena larga en adultos y niños
03 oct. 2022 13h27 HE
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica centrada en el desarrollo de nuevos productos para enfermedades...
Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en Argentina para el tratamiento de la hipofosfatemia ligada al cromosoma X (XLH)
03 oct. 2022 13h25 HE
|
Ultragenyx Pharmaceutical Inc.
BUENOS AIRES, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una empresa biofarmacéutica centrada en el desarrollo y la comercialización de nuevas terapias para enfermedades...
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
09 sept. 2022 20h22 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the...
Ultragenyx to Participate at Citi BioPharma Conference
01 sept. 2022 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
メディア・アドバイザリー：Ultragenyx Japan社、ムコ多糖症VII型の治療薬「メプセヴィ®点滴静注液10㎎®」[ベストロニダーゼ アルファ (遺伝子組換え)]の日本での販売開始を発表
25 août 2022 22h03 HE
|
Ultragenyx Pharmaceutical Inc.
東京発, Aug. 26, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc.は、希少・難治性の重篤な遺伝性疾患に対する新規治療薬の開発および製造販売に注力しているバイオ医薬品企業です。メプセヴィ®点滴静注液10mg [一般名:ベストロニダーゼ アルファ (遺伝子組換え) ]は、ムコ多糖体症VII型 (MPS...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 août 2022 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 août 2022 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...